
What smart money is saying about Fortrea Holdings
2 funds in our archive have pitched Fortrea Holdings — most recently Malborough Marlborough Global SmallCap in August 2026.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Get an email when a fund writes about it
Fund coverage · 2 theses
- Malborough Marlborough Global SmallCapAugust 2026
Fortrea Holdings is a global CRO benefiting from rising R&D spending, greater outsourcing and increasing trial complexity.
Read the full thesis - Curreen CapitalJune 2025
Despite near-term struggles post-spinoff, Fortrea is a high-potential clinical trials firm poised for a turnaround, backed by growing demand, strong industry positioning, and a capital-light model with high barriers to entry—making its current distressed valuation an appealing contrarian bet.
Read the full thesis
Read every full thesis on Fortrea Holdings
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→